BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR
/PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet...
Source: prnewswire.com